Emergent anthrax vaccine receives Singapore HSA approval

BioThrax is indicated to prevent anthrax infection and is also indicated for the active immunization of adults who are at high risk of exposure to anthrax.

BioThrax is manufactured from a culture filtrate, made from a non-virulent strain of Bacillus anthracis.

Emergent president and chief operating officer Daniel Abdun-Nabi said With HSA approval of BioThrax, they look forward to initiating discussions with the government of Singapore, as well as other allied governments that recognize HSA registered products such as Brunei, to help protect their constituents against the threat of anthrax as a biological weapon.